Operator-Assisted Oscilla Audiometry as a Basis for Hearing Aid Fitting (The Oscilla Validation Study)

November 15, 2026 updated by: Lene Dahl Siggaard, Aalborg University Hospital

Validation of Operator-Assisted Oscilla Audiometry as a Diagnostic Tool and Basis for Hearing Aid Fitting in Adults With Uncomplicated Hearing Loss: A Blinded Non-Inferiority Randomised Controlled Trial

The purpose of this study is to find out whether hearing tests performed with the Oscilla A60 audiometer, where the patient largely tests themselves with minimal staff assistance, are accurate enough to be used for diagnosing hearing loss and as the sole basis for fitting hearing aids. Adults referred for their first hearing aids at Aalborg University Hospital will have their hearing tested both with the Oscilla audiometer and by a trained audiology assistant at the same visit. Participants are then randomly assigned to receive hearing aids fitted based on either the Oscilla hearing test or the audiology assistant's hearing test. The main questions are: (1) Do the Oscilla results agree with the audiology assistant's results for both air-conduction and bone-conduction hearing thresholds? (2) Do participants fitted based on the Oscilla test report a hearing benefit that is not worse than that of participants fitted based on the standard test, two months after fitting?

Study Overview

Detailed Description

Demand for audiometric testing in public hearing clinics is increasing due to population ageing. Operator-assisted automated audiometry may expand capacity, but its use as the sole basis for hearing aid prescription, and its accuracy for bone-conduction (BC) thresholds, has not been established. This single-site study at the Department of Audiology, Aalborg University Hospital (locations in Aalborg and Hobro) enrols 268 first-time hearing aid users with uncomplicated, symmetric sensorineural hearing loss.

At Visit 1, all participants undergo both Oscilla A60 audiometry (air conduction [AC] 250-8000 Hz; BC 250-4000 Hz) and standard manual audiometry by an audiology assistant (reference standard), in randomised order. Agreement between methods is assessed with Bland-Altman analysis against pre-specified acceptance criteria (95% CI of bias within ±5 dB; 95% limits of agreement within ±15 dB for AC and ±20 dB for BC). After confirmation of eligibility, participants are randomised 1:1, stratified by hearing loss severity (PTA-4 ≤45 vs >45 dB HL) and location, to hearing aid fitting based on the Oscilla audiogram or the audiology assistant audiogram. All participants are fitted bilaterally with BTE/RIC hearing aids to the NAL-NL2 target, verified with automated real-ear measurements (within ±5 dB). Volume control and app connectivity are disabled until the two-month follow-up. The primary patient-reported outcome is the change in SSQ12 total score from baseline to two months post-fitting, with a non-inferiority margin of -0.81 points. Secondary outcomes are IOI-HA, daily hearing aid use (data logging) and SSQ12 subscales. The study is a clinical investigation under Article 82 of Regulation (EU) 2017/745.

Study Type

Interventional

Enrollment (Estimated)

268

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Lene D Siggaard, MD, PhD
  • Phone Number: +45 20633492
  • Email: lene.dahl@rn.dk

Study Contact Backup

Study Locations

      • Aalborg, Denmark, 9000
        • Department of Audiology, Aalborg University Hospital
        • Contact:
        • Contact:
          • Lene D Siggaard, MD, PhD
          • Phone Number: +4520633492
          • Email: lene.dahl@rn.dk
      • Hobro, Denmark, 9500
        • Hearing Clinic, Aalborg University Hospital
        • Contact:
        • Contact:
          • Lene D Siggaard, MD, PhD
          • Phone Number: +4520633492
          • Email: lene.dahl@rn.dk

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults (≥18 years) referred for first-time hearing aid fitting at the Department of Audiology, Aalborg University Hospital
  • Uncomplicated sensorineural hearing loss as defined by the Danish national clinical guidelines
  • Hearing thresholds exceeding 20 dB HL at two or more frequencies in the range 0.5-4 kHz
  • Pure-tone average (PTA-4; 0.5, 1, 2, 4 kHz) ≥30 dB HL in the better ear
  • Symmetric hearing loss (PTA-4 difference between ears ≤15 dB)
  • Word discrimination score ≥25% (DANTALE I at PTA + 40 dB HL)
  • Danish native speaker
  • No prior hearing aid experience
  • Able to complete questionnaires online or on paper
  • Written informed consent

Exclusion Criteria:

  • Air-conduction thresholds exceeding 80 dB HL at two or more frequencies
  • Air-bone gap >15 dB at one or more frequencies below 1 kHz
  • Fluctuating hearing loss (e.g., Ménière's disease) or ongoing ototoxic medication
  • Ear surgery (ear canal, middle ear or inner ear) within the past 12 months
  • Hearing loss classified as complicated according to national clinical guidelines
  • Visual or motor impairment precluding independent use of the Oscilla system
  • Candidates for in-the-ear hearing aids only (all participants are fitted with BTE or RIC hearing aids)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Oscilla-based fitting

Hearing aids fitted bilaterally to NAL-NL2 targets based on the Oscilla A60 audiogram, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: Paired audiometry and Oscilla-based hearing aid fitting).

At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the Oscilla A60 audiogram as the sole audiometric basis, verified with auto-REM (within ±5 dB of target). Other names: Oscilla A60 Diagnostic Audiometer.

Active Comparator: Manual audiometry-based fitting

Hearing aids fitted bilaterally to NAL-NL2 targets based on the audiogram obtained by a qualified audiology assistant, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: paired audiometry and manual audiometry-based hearing aid fitting).

At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the audiology assistant audiogram, verified with auto-REM (within ±5 dB of target). Standard clinical practice.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Agreement between Oscilla A60 and manual audiometry for air-conduction thresholds
Time Frame: Visit 1 (Week 0)

Bland-Altman mean difference (Oscilla minus manual) and 95% limits of agreement in dB, plus mean absolute difference, at 0.5, 1, 2 and 4 kHz separately. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±15 dB. Both ears included, clustering handled with a mixed-effects model.

Visit 1 (Week 0)
Agreement between Oscilla A60 and manual audiometry for bone-conduction thresholds
Time Frame: Visit 1 (Week 0)

As above for bone-conduction thresholds at 0.5, 1, 2 and 4 kHz. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±20 dB.

Visit 1 (Week 0)
Change in SSQ12 total score
Time Frame: Baseline (Week 0) and 2 months after hearing aid fitting

Speech, Spatial and Qualities of Hearing Scale, 12-item version; total score = mean of 12 items, range 0-10, higher = better. Non-inferiority if the lower bound of the two-sided 95% CI for the between-group difference in change (Oscilla minus control) is above -0.81 points.

Baseline (Week 0) and 2 months after hearing aid fitting

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
IOI-HA total score
Time Frame: 2 months after hearing aid fitting

International Outcome Inventory for Hearing Aids, Danish version; 7 items scored 1-5, total range 7-35, higher = better outcome. Compared between groups

2 months after hearing aid fitting
Daily hearing aid use
Time Frame: From hearing aid fitting to 2 months after fitting

Mean daily hearing aid usage time in hours/day from the hearing aid data log, compared between groups

From hearing aid fitting to 2 months after fitting
Change in SSQ12 subscale scores
Time Frame: Baseline (Week 0) and 2 months after hearing aid fitting

Change in the speech, spatial and qualities subscale scores (each range 0-10, higher = better)

Baseline (Week 0) and 2 months after hearing aid fitting

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lene D Siggaard, MD, PhD, Department of Otolaryngology, Head- and Neck Surgery and Audiology, Aalborg University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

October 31, 2027

Study Completion (Estimated)

October 31, 2027

Study Registration Dates

First Submitted

November 15, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Pseudonymised individual participant data may be shared upon reasonable request after publication, subject to approval under the GDPR and Danish data protection law and a data processing agreement.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe